Waters Stock - Analyst consensus and sector context after Q1 beat
19.06.2026 - 21:29:01 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:25 UTC. Details in the imprint.
Waters (US9418481035) remains a closely watched name in life-science tools after posting strong Q1 2026 numbers in early May. The company raised its full-year guidance at that time, and the stock is now being weighed against peers in a subdued trading week, according to recent analyst summaries.
All news and background on Waters stock
All current headlines, historical news and price data on Waters stock are bundled on the topic page for a compact overview.
What recent numbers show
Waters reported strong Q1 2026 earnings in early May, beating market expectations and lifting its full-year outlook, according to an analyst summary based on the original earnings release. The update highlighted resilient demand in pharmaceutical and biopharma end markets despite a still cautious macro backdrop.
One recent overview cites that HSBC raised its price target on Waters to $435 from $415 while keeping a Buy rating, underlining confidence in the company’s earnings trajectory. The same source notes that the market continues to watch instrument spending trends and China demand as key variables.
Analyst views and consensus levels
Current data compiled by one financial information provider points to an overall Buy consensus on Waters shares, with an average price target around $404.24. This implies modest upside from recent trading levels, though target dispersion remains meaningful.
The same data set lists Waters’ market capitalization at roughly $34.90 billion and shows the stock trading on a trailing price-earnings multiple above 45, reflecting its positioning as a high-quality, recurring-revenue tools franchise. Analyst focus remains firmly on margin resilience, China exposure and the pace of capital spending normalization.
How Waters compares with peers this week
Across the life-science tools sector, Waters is often grouped with Thermo Fisher Scientific and Agilent Technologies, both of which also serve pharma, biotech and applied markets. These peers provide a useful yardstick for revenue growth, capital allocation and valuation.
While large diversified players like Thermo Fisher typically command a broader product base, Waters continues to differentiate through high-performance liquid chromatography and mass spectrometry strengths, particularly in regulated pharma workflows. Compared with some peers, its narrower focus can mean more operating leverage when demand accelerates, but also more cyclicality when labs delay instrument upgrades.
The product engine behind the stock
Waters generates most of its revenue from analytical instruments and related consumables, notably in chromatography and mass spectrometry. Its flagship ACQUITY UPLC systems and associated columns, standards and software are used worldwide to analyze complex chemical and biological samples in pharmaceutical quality control and research labs.
Where the stock trades today
The shares of Waters (US9418481035) trade on the New York Stock Exchange under the ticker WAT at about $355.48 as of 06/18/2026, 16:00 Eastern Time.
Key facts on Waters stock
- Company: Waters Corporation
- ISIN: US9418481035
- WKN: 884340
- Ticker: WAT
- Venue: NYSE
- Price (as of 06/18/2026, 16:00 ET): 355.48 USD
- Market cap: 34.90 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care - Life Sciences Tools & Services
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
